TESAMORELIN nothing more. nothing less.
Tesamorelin is a synthetic GHRH analog with enhanced stability for research applications. Studied in research involving growth hormone signaling, metabolic regulation, and visceral adiposity pathways.
Purity >99.08%Form Lyophilized PowderNo Endotoxins
Order within
—
Notify me when back in stock
For research use only — not for human consumption, therapeutic, or diagnostic use. By adding to cart you acknowledge these terms.
Blank. Credentials
Institutional-grade credentials you can verify
About This Compound
Deep technical insights for clinical research
Synthesis & Purity Overview
Intra-batch variance below 0.25% across peptide identity, potency, and stability testing.
Zero detection of bacterial endotoxins, heavy metals, residual solvents, and microbial contaminants per USP standards.
Chemical Architecture
C₂₂₁H₃₆₆N₇₂O₆₇S
5135.91 g/mol
218949-48-5
trans-3-Hexenoic acid-GHRH(1-44)-NH₂ (modified 44-amino acid growth hormone-releasing factor)
Primary Research Applications
This compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.
Selectively reduces visceral fat accumulation while improving lipid profiles and glycemic parameters in metabolic studies.
Reduces excess abdominal fat through enhanced growth hormone-mediated lipolysis in lipodystrophy models.
Research Community Feedback
"Consistency is paramount in our cellular model testing. Blank's peptides have maintained the tightest purity specs of any RUO vendor we've audited."
Dr. Julian Kessler
Lead Investigator, Biomatrix Labs
"The availability of detailed MS and HPLC data on the product page saved us two days of redundant internal verification. Professional grade synthesis."
Anika S. Singh
Synthetics Quality Control
"Finally, a supplier that doesn't hide behind consumer marketing. Stark, clear, and high-purity. Exactly what a modern lab needs."
Prof. David Emmerich
Applied Peptide Research
Complete The Protocol
Pairs & Supplies
The compounds and tools researchers stack with TESAMORELIN.
Peer-Reviewed Literature
Related Studies
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
New England Journal of Medicine
412 HIV patients receiving tesamorelin 2 mg daily showed selective 18% visceral fat reduction with improved body image over 26 weeks in this landmark NEJM trial.
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients: A Randomized Clinical Trial
JAMA
Tesamorelin-treated group showed VAT decrease of 27.8 cm² versus 5.1 cm² increase in placebo, with triglyceride reductions of 50 mg/dL and modest hepatic fat improvements.
Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial
The Lancet HIV
61 HIV patients with NAFLD showed absolute hepatic fat reduction of 4.1% (37% relative) versus placebo over 12 months, with evidence of reduced fibrosis progression.
Tesamorelin Reduces Carotid Intima-Media Thickness in HIV-Infected Patients with Excess Abdominal Fat
Journal of Clinical Endocrinology & Metabolism
Tesamorelin treatment for 12 months reduced carotid intima-media thickness (cIMT) in HIV patients, suggesting cardiovascular protective effects beyond its established visceral fat reduction benefits.
Effect of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults
Archives of Neurology
Twenty-week GHRH (tesamorelin) treatment improved cognitive function, executive function, and verbal memory in both MCI patients and healthy older adults, with enhanced insulin sensitivity and favorable body composition changes.
Tesamorelin Prevents Onset of Hepatic Steatosis in HIV-Infected Individuals
Clinical Infectious Diseases
Post-hoc analysis of 585 HIV patients showed tesamorelin not only reduced existing liver fat but prevented new-onset hepatic steatosis, with number needed to treat of 7 over 12 months.
From the Lab
Related Blog Posts
Feb 9, 2026
Best Research Peptides in 2026: A Complete Guide by Category
The research peptide landscape in 2026 is broader than it’s ever been. What used to be a handful of compounds…
Jan 19, 2026
What Is Tesamorelin? Growth Hormone-Releasing Research for Body Composition
Tesamorelin is a 44-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) — and it holds a distinction almost no…
Sep 22, 2025
Peptide Side Effects and Safety: What Researchers Need to Know in 2026
Safety data matters. Whether you’re designing a research protocol or evaluating supplier quality, understanding what the published literature says abou...